Publication Details
Abstract
Background: Screening for biomarkers is the process of finding proteins, genes, and other components (also known as tumor markers or biomarkers) that may provide details about malignancy. Each person's cancer has a particular pattern of biomarkers. Some biomarkers influence how specific cancers develop. The aim of this study was to use biomarkers (C7, CK7. CD117) in the early diagnosis of cancer of the bladder and renal cancer.
Methods: A case-control study with 92 participants, 31 individuals in good health as the control group and 61 patients that correspond to the inclusion standards with an age range from (13 to 92) years, Kits were used to measure CLDN7, CK7. CD117 while Enzyme-Linked Immunosorbent Assay (ELISA).
Results: The current study showed significant differences (p< 0.05) in the Age with significant decrease of C7, CK7 and CD117 also showed no significant differences (p 0.057) in the BMI of Renal groups when compared to the case control. Additionally results showed significant differences (p< 0.05) in the Age (61.9) with significant decrease of C7, CK7 and CD117 showed significant increase, also showed no significant difference in BMI (P> 0.285) of Bladder groups when compared to the case control
Conclusion: The results of the current study demonstrated that the biomarkers C7, CK7, and CD117 can be utilized to diagnose renal cancer due to they all had decreasing concentrations, but only C7 and CK7 have decreasing concentrations in bladder cancer counter to (CD117) concentration is rising.